RecruitingPhase 1NCT05003960
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Autism
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment
15 participants
Start Date
Jan 23, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Autism
Eligibility
Inclusion Criteria1
- Diagnosis of Autism
Exclusion Criteria9
- Active infection
- Active cancer
- Chronic multisystem organ failure
- Pregnancy
- Clinically significant Abnormalities on pre-treatment laboratory evaluation
- Medical condition that would (based on the opinion of the investigator) compromise patient's safety
- Previous organ transplant
- Seizure disorder
- Hypersensitivity to sulfur
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALAlloRx
cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05003960
Related Trials
The Alama Project: Autism Outcomes and Neurobehavioral Markers in Young Children Born to Mothers With HIV in Kenya
NCT067031251 location
The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
NCT002716221 location
Reciprocal Imitation Training and Musical Rhythm Sensitivity in Autistic Toddlers
NCT058802251 location
Evaluating Georgia Part C Implementation Outcomes
NCT071482581 location
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
NCT065233871 location